PD-L1 Antibody / B7-H1 / CD274

Overview

Engagement of CD28 by B7-1 (CD80) or B7-2 (CD86) in the presence of antigen promotes T-cell proliferation, cytokine production, differentiation of effector T-cells and the induction of BCLX, a promoter of T-cell survival. Engagement of CTLA4 by B7-1 or B7-2, on the other hand, may inhibit proliferation and interleukin-2 (IL-2) production. PD-L1 is 290-amino acid type I transmembrane protein, which is 20% and 15% identical to B7-1 and B7-2, respectively, has immunoglobulin V-like and C-like domains and a 30-amino acid cytoplasmic tail. PD-L1 does not bind CD28, cytotoxic T-lymphocyte A4 or ICOS (inducible co-stimulator). IL-2, although produced in small amounts, is required for the effect of PD-L1 co-stimulation. PD-L2 protein contains a signal sequence, IgV- and IgC-like domains, a transmembrane region and a cytoplasmic region. The constitutive expression of PD-L1 and PD-L2 on parenchymal cells of heart, lung and kidney suggests that the PD-1-PD-L system could provide unique negative signaling to help prevent autoimmune diseases.

This anti-PD-L1 antibody is supplied as Purified (Mouse, Monoclonal (mouse origin), clone PDL1/2744, Mouse IgG1, kappa, Unconjugated) and is designed to support common target-detection workflows after the on-page specifications.

Key elements and design rationale

• Target: PD-L1
• Format: Purified
• Localization: Cell surface, cytoplasmic
• Species reactivity: Human, Mouse
• Applications (listed): ELISA, WB
• Conjugate: Unconjugated
• Clone and antibody class: Monoclonal (mouse origin), clone PDL1/2744, Mouse IgG1, kappa

Because antibody performance can depend on epitope context, sample preparation, and biological state, interpret signals using appropriate controls and orthogonal evidence when possible.

Biological background

PD-L1 is referenced in public gene/protein resources (e.g., UniProt and NCBI Gene), which provide curated names/synonyms, protein features, and pathway context. When designing assays, consider potential isoforms, post-translational modifications, and cell-type specific expression that may influence observed signal.

Research relevance and current trends

• Profiling PD-L1 expression across model systems, perturbations, and time points to support mechanistic hypotheses.
• Combining antibody-based detection with multi-omics or imaging readouts to link PD-L1 signal with phenotype.
• Using well-matched controls (isotype controls, genetic perturbations, or independent reagents) to strengthen interpretation of target-associated signal.

Common research applications

• ELISA
• WB

Use the listed applications as a starting point and tailor experimental design to your sample type and readout requirements.

Notes for experimental interpretation

• Specificity considerations: closely related family members, isoforms, or PTMs can affect apparent specificity; confirm with independent approaches when critical.
• Controls: include negative controls and, when feasible, genetic or pharmacologic perturbations to support target attribution in your system.
• Species and sample context: differences in sequence, expression, fixation, or extraction conditions can change signal behavior across models.

Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.